Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andy Ryan

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Journal of Medical Genetics|May 7, 2018
Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort studyXin Yang, Goska Leslie, Aleksandra Gentry-Maharaj, et al.
Gynecologic Oncology|June 21, 2020
Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)James Dilley, Matthew Burnell, Aleksandra Gentry-Maharaj, et al.
Genome Medicine|December 23, 2017
Methylation patterns in serum DNA for early identification of disseminated breast cancerMartin Widschwendter, Iona Evans, Allison Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2015
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI VandetanibMonique B Nilsson, Uma Giri, Jayanthi Gudikote, et al.
Trials|January 26, 2021
Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplarJatinderpal K Kalsi, Andy Ryan, Aleksandra Gentry-Maharaj, et al.
International Journal of Cancer|January 28, 2016
Protein Z: A putative novel biomarker for early detection of ovarian cancerMatthew R Russell, Michael J Walker, Andrew J K Williamson, et al.
Cancers|March 6, 2021
Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)Jatinderpal Kalsi, Aleksandra Gentry-Maharaj, Andy Ryan, et al.
Cancers|July 26, 2020
Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal WomenAleksandra Gentry-Maharaj, Oleg Blyuss, Andy Ryan, et al.
The Lancet. Oncology|September 1, 2023
Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trialUsha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, et al.
International Journal of Cancer|October 20, 2023
Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trialChiara Herzog, Allison Jones, Iona Evans, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Journal of Medical Genetics|May 7, 2018
Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort studyXin Yang, Goska Leslie, Aleksandra Gentry-Maharaj, et al.
Gynecologic Oncology|June 21, 2020
Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)James Dilley, Matthew Burnell, Aleksandra Gentry-Maharaj, et al.
Genome Medicine|December 23, 2017
Methylation patterns in serum DNA for early identification of disseminated breast cancerMartin Widschwendter, Iona Evans, Allison Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2015
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI VandetanibMonique B Nilsson, Uma Giri, Jayanthi Gudikote, et al.
Trials|January 26, 2021
Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplarJatinderpal K Kalsi, Andy Ryan, Aleksandra Gentry-Maharaj, et al.
International Journal of Cancer|January 28, 2016
Protein Z: A putative novel biomarker for early detection of ovarian cancerMatthew R Russell, Michael J Walker, Andrew J K Williamson, et al.
Cancers|March 6, 2021
Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)Jatinderpal Kalsi, Aleksandra Gentry-Maharaj, Andy Ryan, et al.
Cancers|July 26, 2020
Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal WomenAleksandra Gentry-Maharaj, Oleg Blyuss, Andy Ryan, et al.
The Lancet. Oncology|September 1, 2023
Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trialUsha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, et al.
International Journal of Cancer|October 20, 2023
Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trialChiara Herzog, Allison Jones, Iona Evans, et al.
Pageof 8